Orchard Therapeutics PLC Sponsored ADR (ORTX)
(Delayed Data from NSDQ)
$20.25 USD
+0.55 (2.79%)
Updated May 3, 2019 04:00 PM ET
After-Market: $20.25 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.25 USD
+0.55 (2.79%)
Updated May 3, 2019 04:00 PM ET
After-Market: $20.25 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?
by Zacks Equity Research
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin
by Zacks Equity Research
Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.
Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Orchard Therapeutics PLC Sponsored ADR (ORTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?
by Zacks Equity Research
Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Orchard Therapeutics PLC Sponsored ADR (ORTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up
by Zacks Equity Research
Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.
Wall Street Analysts Think Orchard Therapeutics PLC Sponsored ADR (ORTX) Could Surge 365.03%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 365% upside potential for Orchard Therapeutics PLC Sponsored ADR (ORTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Orchard Therapeutics PLC Sponsored ADR (ORTX) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?
by Zacks Equity Research
Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.
Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Will Orchard Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Orchard Therapeutics.